...
首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency.
【24h】

A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency.

机译:纤溶酶抑制剂(α2抗纤溶酶)基因内含子6的剪接供体位点突变,具有杂合缺陷和出血倾向。

获取原文
获取原文并翻译 | 示例

摘要

A new case of familial plasmin inhibitor (alpha2 antiplasmin) deficiency is reported. The bleeding symptoms are moderate, happening after surgery or trauma or consisting of abnormal uterine bleeding induced by hormone replacement therapy. It is easily corrected with tranexamic acid. Gene sequencing makes it possible to find a splicing donor site mutation of intron 6, leading to exon 6 skipping. Neither a shortened variant nor an abnormal plasmin interaction was found in plasma by immunoblotting, and fibrin binding is unaffected. The mutation is heterozygous, associated with an intermediate decrease of both antiplasmin activity and antigen levels, and was found in four other family members out of five tested. It is different from the five mutations previously reported. At the time of diagnosis, the patient was living in Artas, France, allowing the defect to be named plasmin inhibitor (alpha2 antiplasmin) Artas.
机译:报告了家族性纤溶酶抑制剂(α2抗纤溶酶)缺乏症的新病例。出血症状中等,在手术或外伤后发生,或由激素替代疗法引起的异常子宫出血组成。用氨甲环酸很容易纠正。基因测序使找到内含子6的剪接供体位点突变成为可能,从而导致外显子6跳过。通过免疫印迹在血浆中未发现缩短的变体或异常的纤溶酶相互作用,并且血纤蛋白结合不受影响。该突变是杂合的,与抗纤溶酶活性和抗原水平的中间降低相关,并且在五个测试的其他四个家族成员中发现。它不同于先前报道的五个突变。诊断时,患者住在法国阿尔塔斯,允许将该缺陷称为纤溶酶抑制剂(α2抗纤溶酶)阿尔塔斯。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号